DX-8951f (Exatecan), a camptothecin derivative, is a promising new antitumor drug currently in phase I clinical trials. The drug exhibits high topoisomerase I inhibitory activity and also high antitumor activity in vitro. It was further found to affect the transport of P-glycoprotein-mediated multidrug resistant cell lines. [1] [2] [3] DX-8951, the anhydrous free base of DX-8951f, contains a lactone ring in its molecule. This lactone of DX-8951 is reversibly hydrolyzed to hydroxy-acid of DX-8951 in alkaline aqueous solution. In a pharmacological study in vitro, the antitumor activity of lactone was found to be higher than that of hydroxy-acid. Thus, the separate quantitation of these forms is important to evaluate the pharmacokinetics and pharmacodynamics of DX-8951.
DX-8951, the anhydrous free base of DX-8951f, contains a lactone ring in its molecule. This lactone of DX-8951 is reversibly hydrolyzed to hydroxy-acid of DX-8951 in alkaline aqueous solution. In a pharmacological study in vitro, the antitumor activity of lactone was found to be higher than that of hydroxy-acid. Thus, the separate quantitation of these forms is important to evaluate the pharmacokinetics and pharmacodynamics of DX-8951.
Other camptothecin derivatives such as irinotecan and topotecan also contain lactone rings. In the assay of irinotecan and topotecan, simultaneous quantitation of their lactone and hydroxy-acid by HPLC were reported. [4] [5] [6] [7] [8] [9] In this paper, we describe a new sensitive and validated HPLC method for lactone and total drug (lactone plus hydroxy-acid) of DX-8951 in mouse plasma using a fluorometric detector. This method can be used successfully to assess the pharmacokinetic study in male mice treated with a single intravenous administration of either lactone or hydroxy-acid of DX-8951.
MATERIALS AND METHODS
Materials DX-8951f, (1S,9S)-1-amino-9-ethyl-5-fluoro-1, 2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo- [de] pyrano-[3Ј, 4Ј : 6,7] indolizino [1,2-b] quinoline-10,13-dione monomethanesulfonate dihydrate was synthesized at Daiichi Pharmaceutical Co., Ltd. (Tokyo).
10) DW-8579, (1S,9S)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-10H,13H-benzo [de] pyrano-[3Ј,4Ј : 6,7]-indolizino-[1,2-b]quinoline-10,13-dione hydrochloride hydrate, was synthesized at Daiichi Pharmaceutical Co., Ltd. (Tokyo) and used as an internal standard (I.S.) (Fig. 1) . The anhydrous free base of DX-8951f is referred to as DX-8951. Methanol (MeOH) and acetonitrile (MeCN) were of HPLC-grade (Kanto Chemical Co. Inc., Tokyo, Japan). All other chemicals were of analytical reagent grade and used without purification. Water purified by a Mill-Q system (Millipore, Milford, MA, U.S.A.) was used.
Chromatographic Conditions The chromatographic system consisted of a Waters 600E multi-solvent pump system, a reverse-phase Puresil C18 column (4.6 mm i.d.ϫ150 mm), and a Waters 474 scanning fluorescence detector (all from Millipore Co., Milford, MA, U.S.A.) set at an excitation wavelength of 365 nm and an emission wavelength of 445 nm. The column temperature was kept at 30°C in a model RCM-100 column oven (Millipore Co.). To the HPLC system equipped with a Waters 717 autosampler (Millipore Co.), 0.08 ml aliquots of samples were injected. The mobile phase, which had been degassed in an ultrasonic bath before use, was a mixture (18 : 82, v/v) of MeCN-0.05 M potassium dihydrogen phosphate (pH 3 adjusted with phosphoric acid). The flow rate was set at 1 ml/min.
Standard Solutions DX-8951 has a lactone ring in its structure which closes and opens reversibly depending on the pH value; it also has a lactone form in acidic pH and a hydroxy-acid form in neutral and basic pH (Fig. 2) . Standard solutions of lactone were prepared by dissolving DX-8951 in 0.04 M Britton-Robinson buffer (pH 3) and diluting with the same buffer. Standard solutions of hydroxy-acid were prepared by dissolving DX-8951 in 0.04 M Britton-Robinson buffer (pH 11) followed by allowing them to stand for more than 24 h at 4°C to complete hydrolysis of the lactone ring, and diluting with the same buffer. A standard solution of DW-8579, I.S., was prepared in 0.04 M Britton-Robinson buffer (pH 3) (180 ng/ml) and stored at 4°C under dark conditions. The drug concentration was expressed as equivalent to DX-8951 (the free form of DX-8951f ).
Sample Preparation Lactone Determination (Procedure I): A C18 Bond Elut cartridge (500 mg) (Varian, Harbor City, CA, U.S.A.) was used for extraction of lactone from 0.1 ml of mouse plasma. The cartridge was pre-conditioned with 2 ml of MeOH and 2 ml of purified water prior to sample application. The 0.1 ml of mouse plasma was diluted with 0.4 ml of 0.01 M phosphate buffer (pH 7.4) and then applied to the conditioned cartridge. To remove hydroxy-acid, the cartridge was washed with 2 ml of purified water and 2 ml of water-MeOH (50 : 50, v/v). Then lactone was eluted with 2 ml aliquots of MeOH-1 M HCl (99 : 1, v/v). To the eluent, internal standard (I.S.) was added (0.02 ml of DW-8579, 180 ng/ml in 0.04 M Britton-Robinson buffer (pH 3)). The I.S. solution was added after extraction of the drug from the cartridge because the lactone form of I.S. was assumed to be unstable under the neutral pH in the cartridge. The eluent was evaporated to dryness by a centrifugal evaporator (Model EC57C, Sakuma, Tokyo, Japan). The residue was dissolved in 0.4 ml of MeCN-0.05 M phosphate buffer (pH 2) (18 : 82, v/v). A 0.08 ml aliquot of the supernatant was injected into the chromatographic system.
Total Drug Determination (Procedure II): The washing process with water-MeOH (50 : 50, v/v) in procedure I was omitted. In procedure II, total drug was eluted with 2 ml aliquots of MeOH-1 M HCl (99 : 1, v/v) from the cartridge. To the eluent, IS was added (0.02 ml of DW-8579, 180 ng/ml in 0.04 M Britton-Robinson buffer (pH 3)), and the eluent was evaporated to dryness by the centrifugal evaporator. The residue was dissolved in 0.4 ml of MeCN-0.04 M phosphate buffer (pH 2) (18 : 82, v/v). A 0.08 ml aliquot of the supernatant was injected into the chromatographic system. Calibration Curves Calibration curves were constructed by plotting the peak area ratio of the analyte to I.S. against the concentration of the analyte. The data were fitted to least squares linear regression with a weighting factor of 1/(concentration) 2 . Recoveries The recoveries of lactone and total drug from mouse plasma were estimated by comparing the peak area obtained from injections of standard solutions with those obtained from the injection of extracts of plasma samples spiked with known concentrations of standard solutions.
Precision and Accuracy Intra-day precision and accuracy of the method were assessed 6 times over the course of one day. Inter-day precision and accuracy were assessed over the course of three days (nϭ6). The limit of quantitation was chosen as the concentration of the lowest calibration standard with an acceptable limit of variance (within 20% for both precision and accuracy).
11)

Stability
The stability of lactone was tested by standing plasma samples at 24°C for 30 min during two freeze-thaw cycles. The samples were thawed in cold water and freezen quickly in dry ice-MeOH. The amount of lactone was then determined by procedure I.
Pharmacokinetic Study A pharmacokinetic study was carried out using BALB/c strain male mice (Japan SLC) weighing 22.0-26.5 g. The dosing solution of lactone was prepared by dissolving DX-8951 in 0.01 M Britton-Robinson buffer (pH 3). The dosing solution of hydroxy-acid was prepared by dissolving DX-8951 in 0.01 M NaOH. Animals were given doses of 15 mg/kg of either lactone or hydroxy-acid in all experiments. After the single bolus injections into the tail vein of unanaesthetized mice, blood samples were taken using a disposable syringe after cutting the carotid artery at 5, 15 and 30 min, and 1, 2, 4 and 6 h after dosing. The blood samples were transferred to plasma separator tubes MICRO-TAINER 5969A (Becton Dickinson Inc.), and then centrifuged. The plasma samples were frozen immediately using dry ice-MeOH and held at Ϫ80°C until assayed.
Plasma concentrations of hydroxy-acid were calculated from the difference between total drug and lactone determinations. Pharmacokinetic parameters were calculated by the software TopFit TM (Gustav Fischer Verlag, Germany). The half-life (t 1/2 ) was obtained by plotting the plasma concentrations on semi-logarithmic paper and calculating the slope (elimination rate constant K e ) of the line determined from a linear regression of the concentrations from 5 min to 2 h after dosing. The t 1/2 was calculated by dividing K e by 0.693. The area under the plasma concentration vs. time curve (AUC inf ) was calculated by the following method. To the calculated value (AUC 6 h ) determined by the trapezoidal method up to 6 h after dosing, was added the value obtained by dividing the plasma concentration at 6 h by the K e . The following method was used to calculate plasma clearance (CLt): CLtϭDose/ AUC inf .
RESULTS AND DISCUSSION
Recoveries Using a C18 solid-phase cartridge, we separated lactone from total drug (lactone plus hydroxy-acid) by a stepwise elution. In procedure I, a separation of lactone and hydroxy-acid was examined using the following plasma samples. Using the plasma samples spiked with hydroxy-acid (300 ng/ml), hydroxy-acid was eluted in the first fraction (water-MeOH, 50 : 50, v/v) with sufficient recovery (96.4%). Using the plasma samples spiked with lactone (3.12-506 ng/ml), lactone was eluted in the fraction of MeOH-1 M HCl (Table  1) . From this recovery data, it was confirmed that lactone was quantitatively separated from total drug, and the recoveries of lactone were acceptable.
In procedure II, the recoveries of total drug were examined as follows. The plasma samples spiked with total drug (3.12-506 ng/ml) were applied to the C18 solid-phase cartridge; then the total drug was eluted with MeOH-1 M HCl (99 : 1, v/v). The recoveries were found to be 81.6-96.8% (Table 1 ) and were viewed as acceptable.
Chromatography and Selectivity Chromatograms of plasma extracts obtained from (A) blank mouse plasma, (B) blank mouse plasma spiked with lactone of DX-8951 (12.5 ng/ml) and I.S. after treatment of procedure I are shown in Fig. 3 . These chromatograms indicate that no endogenous compounds interfered with the detection of lactone or the I.S. at their retention times, which are approximately 10 min and 12 min, respectively.
Calibration Curves Calibration curves (nϭ4) for lactone form prepared by procedure I every fourth day were linear over the concentrations examined (3.12-506 ng/ml) and reproducible with meanϮstandard deviation values for the constants in the regression equation of yϭ(34.5Ϯ4.1)xϩ (Ϫ16.4Ϯ11.3). Correlation coefficients (r) were greater than 0.999.
Calibration curves (nϭ4) for total drug prepared by procedure II every fourth day were linear over the concentrations examined (3.12-506 ng/ml) and reproducible with meanϮ standard deviation values for the constants in the regression equation of yϭ(33.5Ϯ1.2)xϩ(Ϫ1.8Ϯ4.3). Correlation coefficients (r) were greater than 0.997.
Precision and Accuracy The intra-day precision and accuracy were evaluated by analyzing the plasma spiked with lactone (procedure I) or total drug (procedure II) at concentrations of 3.12 to 506 ng/ml in six replicates (Table 2) . Accuracy (RE) was based on the calculation of the found concentration compared to the nominal concentration. The intraday precision (CV) of this method for lactone and total drug were Ͻ5.18 and Ͻ3.46%, respectively. The range of accuracy for lactone was Ϫ6.30 to 14.87%. For total drug, the accuracy ranged from Ϫ5.61 to 3.28%. The inter-day precision and accuracy were evaluated at concentrations of 3.12 to 506 ng/ml ( Table 3 ). The inter-day precision (CV) of this method for lactone and total drug were Ͻ6.07 % and Ͻ7.45%, respectively. The range of accuracy for lactone was Ϫ0.67 to 1.87%; for total drug, the accuracy ranged from Ϫ7.64% to 2.66%. The limit of quantitation of this method using a 0.1-ml plasma sample was determined as 3.12 ng/ml with acceptable precision and accuracy (withinϮ20%). 11) These results indicated that the present method has a satisfactory precision, accuracy and reproducibility.
Stability Assessment of the stability of lactone was very important in this assay method. Lactone exhibited acceptable stability in mouse plasma, when the samples were allowed to stand for 30 min with the loss of Ͻ8.3% (Table 4 ). This instability necessitated quick freezing of the samples after blood sampling in order to stabilize the relatively unstable lactone form. Lactone exhibited acceptable stability in mouse plasma, when exposed to up to two freeze-thaw cycles with the drug loss of Ͻ3.8% (Table 5 ). Pharmacokinetic Study Plasma concentrations of lactone and total drug after intravenous administration of lactone to mice at a dose of 15 mg/kg are shown in Fig. 4 . The concentration of lactone decreased rapidly with a t 1/2 of 0.31 h (Table 6 ). Within 5 min after dosing, the ratio of lactone to total drug in the plasma was 58%. The AUC inf values for lactone and total drug were 1686 and 3239 ng · h/ml, respectively, with a ratio of lactone of 52%.
Plasma concentrations of lactone and total drug after intravenous administration of hydroxy-acid to mice at a dose of 15 mg/kg are shown in Fig. 5 . At 5 min after dosing, the ratio of lactone to total drug was 3%. The AUC inf values for lactone and total drug were 380 and 2902 ng · h/ml, respectively, with a ratio of lactone of 13%. These data demonstrated that after administration of hydroxy-acid to mice, about 90% of the AUC inf values for total drug was hydroxy-acid.
This study demonstrated that the initial plasma concentrations of lactone were significantly higher following dosing with lactone than after dosing of hydroxy-acid. However, by 1 h after dosing of lactone, the plasma concentration of lactone had declined significantly; from 2 to 6 h after dosing these concentrations were similar regardless of the form of DX-8951 administered. Beyond 2 h after dosing, the exposure to the active lactone form of DX-8951 appeared relatively independent of the form administered.
